The American company Moderna said its vaccine was 94.5% effective during the third phase of trials.
This is stated in a press release from the company.
More than 30,000 people in the United States are reportedly involved in the study. It is being conducted in collaboration with the National Institutes of Health and the US Department of Health and Human Services.
Earlier it was reported that Moderna intends to set a price for its coronavirus vaccine at $ 50-60 per vaccination course, which is about $ 25-30 per dose.
Recall that the American pharmaceutical company Pfizer has already sold the majority of its vaccine against coronavirus infection, the effectiveness of which is estimated at 90%.